DE602007003315D1 - Pharmazeutische formulierungen mit dextran mit einem molekulargewicht von 1,0-100 kda und herstellungsverfahren dafür - Google Patents

Pharmazeutische formulierungen mit dextran mit einem molekulargewicht von 1,0-100 kda und herstellungsverfahren dafür

Info

Publication number
DE602007003315D1
DE602007003315D1 DE602007003315T DE602007003315T DE602007003315D1 DE 602007003315 D1 DE602007003315 D1 DE 602007003315D1 DE 602007003315 T DE602007003315 T DE 602007003315T DE 602007003315 T DE602007003315 T DE 602007003315T DE 602007003315 D1 DE602007003315 D1 DE 602007003315D1
Authority
DE
Germany
Prior art keywords
kda
dextran
manufacturing
molecular weight
pharmaceutical formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007003315T
Other languages
German (de)
English (en)
Inventor
Vladimir A Sabetsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BOWS Pharmaceuticals AG
Original Assignee
BOWS Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37930329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602007003315(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BOWS Pharmaceuticals AG filed Critical BOWS Pharmaceuticals AG
Publication of DE602007003315D1 publication Critical patent/DE602007003315D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/042—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602007003315T 2006-01-18 2007-01-17 Pharmazeutische formulierungen mit dextran mit einem molekulargewicht von 1,0-100 kda und herstellungsverfahren dafür Active DE602007003315D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0600091A SE0600091L (sv) 2006-01-18 2006-01-18 Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin
PCT/SE2007/050027 WO2007084068A1 (en) 2006-01-18 2007-01-17 Pharmaceutical formulations comprising dextran with molecular weight of 1.0-100kda and processes for their preparation

Publications (1)

Publication Number Publication Date
DE602007003315D1 true DE602007003315D1 (de) 2009-12-31

Family

ID=37930329

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007003315T Active DE602007003315D1 (de) 2006-01-18 2007-01-17 Pharmazeutische formulierungen mit dextran mit einem molekulargewicht von 1,0-100 kda und herstellungsverfahren dafür

Country Status (16)

Country Link
US (3) US20080305139A1 (https=)
EP (2) EP2153850A1 (https=)
JP (1) JP2009523791A (https=)
CN (1) CN101370523A (https=)
AR (1) AR059071A1 (https=)
AT (1) ATE448798T1 (https=)
AU (1) AU2007206087A1 (https=)
BR (1) BRPI0706543A2 (https=)
CA (1) CA2636173A1 (https=)
DE (1) DE602007003315D1 (https=)
ES (1) ES2336380T3 (https=)
MX (1) MX2008008924A (https=)
RU (1) RU2008133635A (https=)
SE (1) SE0600091L (https=)
TW (1) TW200738279A (https=)
WO (1) WO2007084068A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200501422A1 (ru) * 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
US9023376B2 (en) * 2008-06-27 2015-05-05 The University Of Akron Nanofiber-reinforced composition for application to surgical wounds
KR101003331B1 (ko) 2010-05-11 2010-12-23 조강선 피부 충전제 조성물
AU2015221390B2 (en) * 2014-02-20 2019-03-07 Ortho Regenerative Technologies Inc. Lyophilized polymer scaffold compositions, processes for preparation and use in anabolic wound repair
US10426796B2 (en) * 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713249A (en) * 1981-11-12 1987-12-15 Schroeder Ulf Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof
SE8204244L (sv) * 1982-07-09 1984-01-10 Ulf Schroder Kristalliserad kolhydratsmatris for biologiskt aktiva substanser
DE3500268A1 (de) * 1985-01-05 1986-07-10 Hoechst Ag, 6230 Frankfurt Praeparate mit verzoegerter wirkung, verfahren zu deren herstellung sowie entsprechende mittel zur human- bzw. veterinaermedizinischen anwendung
EP0247077A1 (en) 1985-10-22 1987-12-02 ROBINSON, Eric Process for cell immobilisation
JPS62152816A (ja) * 1985-12-27 1987-07-07 Sumitomo Pharmaceut Co Ltd ゲル状高分子の成形方法
JPH0720483B2 (ja) * 1987-05-29 1995-03-08 住友製薬株式会社 高粘度糊状組成物成形体の乾燥法
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
US7087244B2 (en) 2000-09-28 2006-08-08 Battelle Memorial Institute Thermogelling oligopeptide polymers
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
EP1074248A1 (en) 1999-07-08 2001-02-07 Arnold Hilgers Delivery system for biological material
WO2001078687A1 (en) * 2000-04-18 2001-10-25 Peptron Inc. Injectable sustained release pharmaceutical composition and processes for preparing the same
EP1184032A1 (en) * 2000-08-31 2002-03-06 OctoPlus B.V. Dextran hydrogels
EP1429731B1 (en) 2001-09-19 2007-01-03 Elan Pharma International Limited Nanoparticulate insulin formulations
EA200501422A1 (ru) * 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
TW200603843A (en) * 2004-04-20 2006-02-01 Technology Dev Company Ltd Tissue enhancement implant and method

Also Published As

Publication number Publication date
CN101370523A (zh) 2009-02-18
ATE448798T1 (de) 2009-12-15
AR059071A1 (es) 2008-03-12
EP2153850A1 (en) 2010-02-17
EP1973570B1 (en) 2009-11-18
CA2636173A1 (en) 2007-07-26
HK1125041A1 (en) 2009-07-31
US20080305139A1 (en) 2008-12-11
EP1973570A1 (en) 2008-10-01
MX2008008924A (es) 2008-09-05
SE529040C2 (sv) 2007-04-17
US20100172950A1 (en) 2010-07-08
BRPI0706543A2 (pt) 2011-03-29
WO2007084068A1 (en) 2007-07-26
AU2007206087A1 (en) 2007-07-26
SE0600091L (sv) 2007-04-17
US7781400B2 (en) 2010-08-24
TW200738279A (en) 2007-10-16
JP2009523791A (ja) 2009-06-25
RU2008133635A (ru) 2010-02-27
ES2336380T3 (es) 2010-04-12
US20090281020A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
CY2015009I2 (el) Ινδολινονες υποκατεστημενες στη θεση 6, η παραγωγη αυτων και η χρηση αυτων ως φαρμακευτικα μεσα
CR10733A (es) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
CL2007003444A1 (es) Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
DE112006001565A5 (de) Nanopartikel-Wirkstoff-Konjugate
CY2013002I1 (el) 8-[3-αμινο-πιπεριδιν-1-υλο]-ξανθινες, παραγωγη αυτων και χρηση τους ως φαρμακων
PL1909755T3 (pl) Nanotechnologia cyklodekstryn do dostarczania leku do oczu
NL1029105A1 (nl) Tetraazabenz[e]azuleenderivaten en analogen daarvan.
DE502005002105D1 (de) 4-benzimidazol-2-yl-pyridazin-3-on-derivative, ihre herstellung und verwendung in arzneimitteln
EP1933936A4 (en) IMPREGNATED ENVELOPE OF MEDICAMENT
DE602005012107D1 (de) Pharmazeutische formulierungen mit einem antibioti
DE602005006815D1 (de) 2-carbamid-4-phenylthiazol-derivate, deren herstellung und therapeutische verwendung
DE602005019564D1 (de) Hylenglykol mit einem molekulargewicht unter 600 dalton
DE602007003315D1 (de) Pharmazeutische formulierungen mit dextran mit einem molekulargewicht von 1,0-100 kda und herstellungsverfahren dafür
ATE389398T1 (de) Neue azabicyclische derivate, herstellungsverfahren dafür und sie enthaltende pharmazeutische zusammensetzungen
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
DK1986611T3 (da) Proteinpolymernanopartikler med repeat-sekvens, der eventuelt indeholder aktive stoffer, og fremstilling heraf
ATE542806T1 (de) Diarylmethylpiperazinderivate, deren herstellung und deren verwendung
ATE437857T1 (de) Neuartige pyridinylaminalkylen- und pyridinyloxalkylen-cyclopropanamine, herstellungsverfahren dafür und pharmazeutische zusammensetzungen damit
ZA200710146B (en) New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
ITTO20060659A1 (it) Arresto di fondo corsa per una cerniera lampo, e cerniera lampo comprendente un tale arresto di fondo corsa.
ATE466863T1 (de) Neue aminopyrrolo-ä1,2-aü-indol- und aminopyridazino-ä1,6-aü-indol-derivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen damit
ATE420118T1 (de) Biotinylierte hexadecasaccharide, pharmazeutische zusammensetzungen daraus und deren verwendung
FR2912404B1 (fr) Derives d'azabicycloalkane,leur preparation et leur application en therapeutique.
DE602006018617D1 (de) Pharmazeutische zusammensetzung mit 2,3-dihydro-6-nitroimidazoä2,1-büoxazolderivaten
ZA200705782B (en) Meta-substituted thiazolidinones, the production thereof and their use as medicaments

Legal Events

Date Code Title Description
8363 Opposition against the patent